

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.427C15APPLICATION NO.
09/593,793
**SIXTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**
 (Use several sheets if necessary)

 APPLICANTS
 Jiangchun Xu et al.

 FILING DATE
 June 13, 2000

 GROUP ART UNIT
 1642 JUL 08 2004

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	TECH CENTER SUBCLASS	IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
	AK				
	AL				
	AM				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DB	AP	Aspinall, J.O. et al., "Differential Expression of Apolipoprotein-D and Prostate Specific Antigen in Benign and Malignant Prostate Tissues," <i>Journal of Urology</i> 154: 622-628, August 1996.
DB	AQ	Fannon, M.R., "Gene expression in normal and disease states – identification of therapeutic targets," <i>Trends in Biotechnology</i> 14: 294-298, August 1996.
DB	AR	Garde, S.V. et al., "Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP)," <i>Cancer Letters</i> 78: 11-17, 1994.
DB		GenBank Database, Accession No. AA112574, May 29, 2003.
DB		Murphy, G. et al., "Comparison of Prostate Specific Membrane Antigen, and Prostate Specific Antigen Levels in Prostatic Cancer Patients," <i>Anticancer Research</i> 15: 1473-1480, 1995.

EXAMINER

DATE CONSIDERED

8/23/04

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).